SunTrust Banks reaffirmed their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report report published on Friday morning. The brokerage currently has a $65.00 price objective on the stock.
A number of other equities analysts also recently issued reports on the company. Piper Jaffray Companies reissued an overweight rating and set a $53.70 target price (down from $67.00) on shares of Crispr Therapeutics in a research note on Friday. JMP Securities assumed coverage on Crispr Therapeutics in a research note on Thursday, March 8th. They set an outperform rating and a $69.00 target price for the company. Barclays increased their target price on Crispr Therapeutics from $29.00 to $59.00 and gave the stock an overweight rating in a research note on Wednesday, March 7th. ValuEngine raised Crispr Therapeutics from a sell rating to a hold rating in a research note on Wednesday, February 28th. Finally, Citigroup increased their target price on Crispr Therapeutics from $20.00 to $51.00 and gave the stock a neutral rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Crispr Therapeutics has an average rating of Buy and a consensus price target of $53.53.
Crispr Therapeutics (CRSP) opened at $56.80 on Friday. The stock has a market capitalization of $2,610.00 and a P/E ratio of -36.41. Crispr Therapeutics has a one year low of $13.50 and a one year high of $61.24.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its holdings in shares of Crispr Therapeutics by 17.2% in the 4th quarter. Wells Fargo & Company MN now owns 21,517 shares of the company’s stock worth $505,000 after acquiring an additional 3,165 shares during the period. ARK Investment Management LLC grew its holdings in shares of Crispr Therapeutics by 22.8% in the 4th quarter. ARK Investment Management LLC now owns 31,388 shares of the company’s stock worth $737,000 after acquiring an additional 5,833 shares during the period. Creative Planning acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth approximately $243,000. Paloma Partners Management Co acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth approximately $290,000. Finally, Ark Investment Management LLC acquired a new stake in shares of Crispr Therapeutics in the 2nd quarter worth approximately $206,000. Institutional investors and hedge funds own 27.29% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Crispr Therapeutics (CRSP) Stock Rating Reaffirmed by SunTrust Banks” was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3258795/crispr-therapeutics-crsp-stock-rating-reaffirmed-by-suntrust-banks.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.